Engineered Macrophage Therapy Shows Promise Against Liver Fibrosis in Preclinical Study
RTX001, a regenerative macrophage cell therapy, reduced liver inflammation and fibrosis in mouse models ahead of Phase I/II trial results.
Summary
Resolution Therapeutics has shared new preclinical data on RTX001, an engineered macrophage cell therapy targeting end-stage liver disease. Tested in mouse models, RTX001 demonstrated a clear pharmacological profile, safety, and the ability to reduce liver enzymes, inflammation, and fibrosis — key drivers of liver failure. The therapy uses specially engineered immune cells called macrophages, which are reprogrammed to fight inflammation and tissue scarring rather than promote it. The company, a spinout from the University of Edinburgh, presented these findings at the ASGCT Annual Meeting in Boston. Interim human trial results from the Phase I/II EMERALD trial are expected in the second half of 2026. Beyond liver disease, RTX001 is also being explored for graft-versus-host disease and lung fibrosis.
Detailed Summary
Liver fibrosis and end-stage liver disease represent a major unmet medical need, with few effective therapies capable of reversing tissue scarring once it takes hold. Resolution Therapeutics is attempting to change that with RTX001, an engineered regenerative macrophage therapy designed to reduce inflammation and halt or reverse fibrosis in the liver.
New preclinical data presented at the ASGCT Annual Meeting in Boston show RTX001 performs well in mouse models across several key metrics. The therapy demonstrated a defined pharmacology and pharmacokinetic profile, meaning researchers can track how it behaves in the body. Crucially, it reduced liver enzymes — a standard marker of liver damage — alongside measurable reductions in inflammation and fibrosis markers.
Macrophages are immune cells that normally regulate inflammation and tissue repair. RTX001 takes this a step further by engineering these cells to actively promote regeneration and suppress damaging inflammatory responses. This approach differs from small-molecule drugs by using living cells as the therapeutic agent, potentially enabling more targeted and durable effects.
Resolution Therapeutics is a University of Edinburgh spinout with labs in Edinburgh and London. The company is currently running a Phase I/II human trial called EMERALD, with interim results expected in the second half of 2026. These human data will be the first real test of whether the preclinical promise translates to patients with end-stage liver disease.
Beyond liver disease, the company is exploring RTX001 for graft-versus-host disease and lung fibrosis — conditions that share inflammatory and fibrotic pathways. For longevity-focused readers, this research matters because chronic liver disease and fibrosis are significant contributors to accelerated biological aging and reduced healthspan. However, all current data are preclinical; human efficacy remains unproven until trial results emerge.
Key Findings
- RTX001 reduced liver enzymes, inflammation, and fibrosis markers in mouse models with acceptable safety profile.
- Engineered macrophages reprogram immune response to actively promote liver tissue regeneration rather than damage.
- Phase I/II EMERALD human trial interim results expected H2 2026 — key milestone for clinical validation.
- RTX001 is being explored beyond liver disease for lung fibrosis and graft-versus-host disease.
- Cell therapy approach may offer more durable, targeted anti-fibrotic effects than conventional small-molecule drugs.
Methodology
This is a corporate news report summarizing preclinical conference data from Resolution Therapeutics, published by Longevity.Technology. The evidence basis is mouse model studies; no peer-reviewed publication is cited. Claims originate from the company itself, introducing potential promotional bias.
Study Limitations
All efficacy data are from mouse models, which frequently fail to translate to humans. No peer-reviewed paper is referenced, and findings come from a company press release. Independent replication and Phase I/II human trial data are required before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.